Auph short interest.
In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in AUPH / Aurinia Pharmaceuticals Inc. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price.
Biotech stocks are very interest rate sensitive and I suspect once the Federal Reserve pivots and begins cutting interest rates, AUPH and the rest of the sector's stocks will move materially ...Short interest, stock short squeeze, short interest ratio & short selling data positions for NASDAQ, NYSE & AMEX stocks to find shorts in the stock market.WebAUPH has no debt and, even better, 400 millions in cash. Good market penetration so far (100 patients Q1, 400 Q2) and guidance provided for the end of the year (40-50 millions) with great expectations for the next years (200 in 2022, 400 in 2023, sales peak at 1.5 billions) ... The short interest. Since the FDA Approval in Jan 2021, the stock ...Track Aurinia Pharmaceuticals Inc (AUPH) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsMar 7, 2022 · The actual guidance provided by AUPH in its earnings release on Feb 28, fell way short of that Wall St number: "For fiscal year 2022, the Company is providing net revenue guidance of $115 to $135 ...
The European Commission has approved Aurinia Pharmaceuticals' ( NASDAQ: AUPH) Lupkynis (voclosporin) for lupus nephritis. The approval triggers a $30M milestone payment from partner Otsuka ...Cantor Fitzgerald Reiterates Aurinia Pharmaceuticals (AUPH) Overweight Recommendation. ... Highest Short Float; Owners Retail Ownership Most Popular Funds Activist Investors Fund Sentiment - World. United States Canada UK Hong Kong Japan Australia New Zealand.
The short interest in Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) is 17.19 million shares and it means that shorts have 11.64 day(s) to cover. The consensus price target of analysts on Wall Street is $13.21, which implies an increase of 34.6% to the stock’s current value.
Biocept, Inc. (NASDAQ:BIOC – Get Free Report) was the target of a significant decline in short interest in July. As of July 15th, there was short interest totalling 26,500 shares, a decline of 6.7% from the June 30th total of 28,400 shares. Approximately 1.8% of the company’s stock are sold short. Based on an average […]WebAuthor: u/Yolteotl (Karma: 16452, Created: Feb-2013). AUPH: Best treatment against Lupus nephritis, still widely undervalued, buyout candidate and…Aurinia Pharmaceuticals Stock (NASDAQ:AUPH), Short Interest Report. Short interest for Aurinia Pharmaceuticals gives investors a sense of the degree to …Data Link's cloud-based technology platform allows you to search, discover and access data and analytics for seamless integration via cloud APIs. Register for your free account today at data ...
May 22, 2023 · @PITX3 not really great short squeeze potential, more like short caress. 11% of float takes 5 - 6 days to cover. From mid-April to mid-May the short position decreased by 2M down to 15.5M, 11% of ...
Still, when we talk about a small-cap biotech that is clearly drawing the interest of some big pharma guys, we can say that AUPH's current valuation is very low, without but surely with buyout ...
Loan debt generally consists of two parts: the principal, or the total amount of the loan, and interest, or the extra amount the lender charges as compensation for what you’ve borrowed.Aurinia Pharmaceuticals (AUPH) has begun to examine strategic alternatives that could include a potential sale or merger. ... Also, with 11%+ short interest, there should be some "motivated ...Initially, Lupkynis seemed to be a promising treatment for LN, but its adoption has fallen short of expectations, as shown by Aurinia's failure to meet its 2022 revenue projections ($115-$135 ...Dec 1, 2023 · A high-level overview of Aurinia Pharmaceuticals Inc. (AUPH) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. ... Short Interest ... E131: 2024 Fantasy President picks, debt ceiling agreement, Dollar dominance & moreWeb
Based on recent acquisitions, Aurinia ( AUPH) would be more likely to see $18–$20 per share in a takeover, RBC analyst Douglas Miehm, who has an outperform rating with a $13 price target on AUPH ...AUPH - Short squeeze stock short interest data and short selling information for shares of Aurinia Pharmaceuticals Ord. Short interest stock data available for NASDAQ, NYSE, AMEX, OTCBB and Pink Sheets stocks available from shortsqueeze.com.M&A season started some weeks ago with Trilium / Pfizer, Sanofi bought Kadmon, etc... AUPH is one of the best candidate for the big pharmas. A weird Press Release appeared a couple of weeks ago on different websites, about a 35+ acquisition by a big pharma, it was later asked to be removed by the company from Benzinga. The short interest Find out why interest in selling AUPH stock has not subsided in some quarters. ... @PITX3 not really great short squeeze potential, more like short caress. 11% of float takes 5 ...We would like to show you a description here but the site won’t allow us.
Aurinia Pharma press release ( NASDAQ: AUPH ): Q2 GAAP EPS of -$0.08 beats by $0.11. Revenue of $41.49M (+47.2% Y/Y) beats by $3.98M. Increases 2023 revenue guidance range to $150 - $160 million ...
Track Aurinia Pharmaceuticals Inc (AUPH) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsAurinia Pharmaceuticals (AUPH) has begun to examine strategic alternatives that could include a potential sale or merger. ... Also, with 11%+ short interest, there should be some "motivated ...May 22, 2023 · @PITX3 not really great short squeeze potential, more like short caress. 11% of float takes 5 - 6 days to cover. From mid-April to mid-May the short position decreased by 2M down to 15.5M, 11% of ... Nov 24, 2023 · Short interest in Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) saw shorts transact 17.28 million shares and set a 9.89 days time to cover. Analysts on Wall Street suggest a consensus price target of $13.21, implying an increase of 29.75% to the stock’s recent value. Short Float / Ratio: 13.17% / 8.88: Perf Quarter-4.23%: Sales: 158.85M: P/S: 8.19: EPS this Y: 31.36%: Inst Trans: 9.16%: Short Interest: 17.19M: Perf Half Y-5.03%: Book/sh: 2.73: P/B: 3.32: EPS next Y: 29.71%: ROA-14.80%: Target Price: 13.21: Perf Year: 76.61%: Cash/sh: 2.35: P/C: 3.85: EPS next 5Y-ROE-18.94%: 52W Range: 4.07 - 12.43: Perf YTD ... Mar 21, 2023 · Biotech stocks are very interest rate sensitive and I suspect once the Federal Reserve pivots and begins cutting interest rates, AUPH and the rest of the sector's stocks will move materially ... Aurinia Pharmaceuticals Stock (NASDAQ: AUPH) stock price, news, charts, stock research, ... Profile News Analyst Ratings Guidance Dividends Earnings Insider Trades Ideas …Meanwhile, Jefferies analyst Maury Raycroft, with a Buy rating on Aurinia ( AUPH ), has cut the per share target to $29 from $34 to imply a premium of ~142% to the last close. Raycroft attributes ...
The average one-year price target for AUPH / Aurinia Pharmaceuticals Inc is $14.28. The forecasts range from a low of $12.12 to a high of $15.75. A stock’s price target is the price at which analysts consider it fairly valued with respect to its projected earnings and historical earnings. Analysts typically set price targets that correspond ...
As of November 15th, there was short interest totaling 30,500 shares, a decrease of 27.2% from the October 31st total of 41,900 shares. Based on an average daily volume of 37,400 shares, the short-interest ratio is presently 0.8 days. Currently, 1.0% of the company's shares are sold short. ... (AUPH), Arch Therapeutics ...Web
M&A season started some weeks ago with Trilium / Pfizer, Sanofi bought Kadmon, etc... AUPH is one of the best candidate for the big pharmas. A weird Press Release appeared a couple of weeks ago on different websites, about a 35+ acquisition by a big pharma, it was later asked to be removed by the company from Benzinga. The short interest 2023-03-14 Short sale volume (not short interest) for $AUPH is 32%. http://shortvolumes.com/?t=AUPH $XLV 48% $AEZS 50% $REGN 54%. 16 Mar 2023 00:36:01WebShort Squeeze - Canada; Short Squeeze - Hong Kong; Highest Cost to Borrow; Highest Short Float; Owners Retail Ownership Most Popular Funds Activist Investors Fund Sentiment - World. United States Canada UK Hong Kong Japan Australia New Zealand. Germany Switzerland Spain Poland Netherlands Greece France Ireland Italy Belgium …WebCash received for interest $ 2,713 $ 528 Cash paid for income taxes $ (277) $ (779) Cash paid for amounts included in the measurement of lease liabilities $ (531) $ (572) Supplemental disclosure of noncash transactions: Finance right-of-use asset obtained in exchange for lease obligations (monoplant) $ 117,622 $ —Thinking about investing in Aurinia Pharmaceuticals because of the upcoming earnings date annual report or stock price forecast? Check out AUPH short interest and earnings date annual report by comparing AUPH insider trading history and institutional ownership breakdown to maximise your investment return on the stock market.AUPH / Aurinia Pharmaceuticals Inc short borrow fee rates are shown in the following table. This table shows the interest rate that must be paid by a short seller of US:AUPH to the lender of that security. This fee is shown as an annual percentage rate (APR).29 Sep 2021 ... We follow 790 shorted U.S. domestic biotech stocks with total short interest of $54.5 billion. Short selling in these stocks is highly ...Short Interest. Most Shorted. Largest Increase. Largest Decrease. ... Cramer said Aurinia Pharmaceuticals Inc. AUPH is a Canadian company that "I don’t really have a lot of confidence in, ...WebAurinia Pharmaceuticals ( NASDAQ: AUPH) named Dr. Robert Foster as a new board member Thursday as part of an agreement with its major shareholder and investment management firm, MKT Capital Ltd ...Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH – Get Free Report) (TSE:AUP) was the target of a large growth in short interest in July. As of July 15th, there was short interest totalling 16,710,000 shares, a growth of 6.8% from the June 30th total of 15,650,000 shares. Based on an average daily trading volume, of 2,430,000 shares, the […]@PITX3 not really great short squeeze potential, more like short caress. 11% of float takes 5 - 6 days to cover. From mid-April to mid-May the short position decreased by 2M down to 15.5M, 11% of ...
VFS. VinFast Auto Ltd. Ordinary Shares. $34.50 -2.53 -6.83%. MULN. Mullen Automotive, Inc. Common Stock. $0.813 +0.013 +1.62%. Find the latest Insider Activity data for Aurinia Pharmaceuticals Inc ...WebAug 2, 2023 · Aurinia Pharma (AUPH) is scheduled to announce Q2 earnings results on Thursday, August 3rd, before market open.The consensus EPS Estimate is -$0.18 (+28.0% Y/Y) and the consensus... Based on recent acquisitions, Aurinia ( AUPH) would be more likely to see $18–$20 per share in a takeover, RBC analyst Douglas Miehm, who has an outperform rating with a $13 price target on AUPH ...Initially, Lupkynis seemed to be a promising treatment for LN, but its adoption has fallen short of expectations, as shown by Aurinia's failure to meet its 2022 revenue projections ($115-$135 ...Instagram:https://instagram. how to trade xsp optionsbest financial etfssandp 500 buybackstocks splitting in 2023 M&A season started some weeks ago with Trilium / Pfizer, Sanofi bought Kadmon, etc... AUPH is one of the best candidate for the big pharmas. A weird Press Release appeared a couple of weeks ago on different websites, about a 35+ acquisition by a big pharma, it was later asked to be removed by the company from Benzinga. The short interestShort Interest : 17.19M: Short Previous Month : 17.28M: Short % of Shares Out : 11.97%: Short % of Float : 12.21%: Short Ratio (days to cover) 11.64 pre sale iphone 15is roku a good stock to buy Exhibit 99.1 Aurinia Pharmaceuticals Inc. Interim Condensed Consolidated Statements of Financial Position (Unaudited) As at March 31, 2019 (expressed in thousands of US dollars) March 31, 2019 $ December 31, 2018 $ Assets Current assets Cash and cash equivalents 140,359 117,967 Short term investments (note 4) 3,975 7,889 Accounts receivable and ...The SPDR S&P Biotech ETF, one of the largest U.S. biotech ETFs, has a short interest percent of float of 57.7%, according to data from S3 Partners. pandora fitbit Initially, Lupkynis seemed to be a promising treatment for LN, but its adoption has fallen short of expectations, as shown by Aurinia's failure to meet its 2022 revenue projections ($115-$135 ...A high-level overview of Aurinia Pharmaceuticals Inc. (AUPH) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. ... Short Interest ...